APRIL 2023

SOUTH DAKOTA BOARD OF PHARMACY

newsletter to promote pharmacy and drug law compliance

South Dakota Board Welcomes Newly Registered Pharmacists and Pharmacies

Congratulations to the following seven candidates who recently met licensure requirements and were licensed as new pharmacists in South Dakota: Zachary Buchner, Jody Coburn, Megan Krol, Lisa Ohnstad, Adrienne Rivera, Alyssa Schweitzer, and Conroy Thompson.

There was one new South Dakota full-time pharmacy license issued: Stronghold Pharmacy, change of ownership from Homer's Pharmacy, Arlington, SD, License #100-2086. There was one new part-time South Dakota pharmacy license issued: Avera McKennan, dba Avera Long-Term Care Pharmacy Nexsys ADC #6, Aberdeen, SD, License #200-1760.

MAT Act Signed Into Law

By Jensen Kiesow, P4 Regulatory Intern

On December 29, 2022, President Joseph R. Biden signed the Consolidated Appropriations Act of 2023 into law. This bill included legislation to address the opioid crisis, including the Mainstreaming Addiction Treatment Act (MAT Act), which officially eliminated the DATA-Waiver Program. The DATA-Waiver Program required prescriber education on opioid use disorder (OUD) through the Substance Abuse and Mental Health Services Administration and subsequent assignment of an "X DEA number" by Drug Enforcement Administration (DEA) to prescribe buprenorphine for OUD. On January 12, 2023, DEA provided a Dear Registrant Letter stating this. The requirement of an

National Pharmacy Compliance News

A Service of the National Association of Boards of Pharmacy Foundation (NABPF)

Visit NABP's website for the latest regulatory updates and news from FDA, USP, NABP, and more.

Read National News

X-DEA number for prescribing buprenorphine products has been eliminated. There will no longer be any limitations or caps on the number of patients a prescriber may treat for OUD. The intent of eliminating this policy is to increase access to buprenorphine to patients suffering from OUD, help patients sustain recovery, and prevent further opioid overdoses.

All prescriptions for buprenorphine require a standard DEA registration number only. There is no longer a requirement for an "X-DEA" number on any prescriptions going forward. Further, it was previously required for the prescriber to include, on the prescription, whether the patient is taking buprenorphine for pain or OUD treatment. This is also no longer required.

With the elimination of the DATA Waiver and its associated educational requirement, DEA now adds new training requirements for all prescribers. As of June 27, 2023, all prescribers are required to obtain eight hours of prescribing training for the treatment of OUD with medication prior to obtaining or renewing a DEA number. The new training requirement for prescribers does not impact changes related to the elimination of the X-DEA number as described above, and pharmacists will not have visibility into whether the prescriber has met the requirement. If the training is not completed, the prescriber will lose their DEA number and the ability to prescribe controlled substances (CS). This could adversely affect pharmacists trying to take care of patients. Encourage prescriber colleagues to complete the training as soon as possible.

FDA Acts to Restrict Unlawful Import of Xylazine, or 'Tranq'

Food and Drug Administration (FDA) announced that it has taken action to restrict the unlawful entry of xylazine active pharmaceutical ingredients and finished dosage form drug products into the country to address a growing public health concern. The chemical xylazine has increasingly been found in drugs, such as illicitly manufactured fentanyl, and is increasingly detected in overdose deaths. This action aims to prevent the drug from entering the United States market for illicit purposes, while maintaining availability for its legitimate uses in animals.

Xylazine is not an opioid, but it is extremely dangerous because it can depress breathing, blood pressure, heart rate, and body temperature to critical levels. Additionally, people who inject drugs containing xylazine can develop severe skin wounds and patches of dead and rotting tissue that easily become infected and, if left untreated, may lead to amputation. The wounds can develop in areas of the body away from the injection site and may become life threatening. The agency previously communicated to health care providers about the risks to patients exposed to xylazine in illicit drugs.

First OTC Test to Detect and Differentiate Between the Flu and COVID-19 Issued EUA

On February 24, 2023, FDA issued an emergency use authorization (EUA) for the first over-the-counter (OTC) at-home diagnostic test that can differentiate and detect influenza A and B,

commonly known as the flu, and SARS-CoV-2, the virus that causes the coronavirus disease 2019 (COVID-19). The Lucira COVID-19 & Flu Home Test is a single-use at-home test kit that provides results from self-collected nasal swab samples in roughly 30 minutes. What a game changer this is in at-home testing.

PDMP Update

By Melissa DeNoon, PDMP Director

Year 2022 Top Ten CS to SD Patients	RXs	Quantity	Days of Supply	Avg Quant/Rx
HYDROCODONE BITARTRATE/ACETAMINOPHEN	142,988	7,645,348	1,793,101	53
DEXTROAMPHETAMINE SULF-SACCHARATE/AMPHETAMINE SULF-ASPARTATE	112,591	4,960,521	3,339,725	44
TRAMADOL HCL	111,543	6,688,229	1,890,020	60
LORAZEPAM	75,913	3,218,030	1,664,110	42
METHYLPHENIDATE HCL	71,352	2,987,793	2,129,299	42
CLONAZEPAM	69,781	3,778,605	2,050,274	54
ZOLPIDEM TARTRATE	69,388	2,430,871	2,426,286	35
OXYCODONE HCL	52,172	2,686,596	651,153	51
ALPRAZOLAM	49,487	2,559,719	1,277,355	52
LISDEXAMFETAMINE DIMESYLATE	47,170	1,437,899	1,422,196	30

Trending PDMP Utilization by SD Prescribers and Pharmacists





Trending SD Patients' Opioid Prescriptions







PharmaDrop Drug Take-Back Program





Board Meeting Dates

Please check the Board Meetings page on the South Dakota Board of Pharmacy's website for the time, location, and agenda for future Board meetings.

Board of Pharmacy Members

Ashley Hansen, Aberdeen, SD

Cheri Kraemer, Parker, SD

Tom Nelson, Spearfish, SD

Curtis Rising, Rapid City, SD

Dan Somsen, Yankton, SD

Board of Pharmacy Staff Directory

Board Office General Email: PharmacyBoard@state.sd.us

Office Phone: 605/362-2737; Office Fax: 605/362-2738

Kari Shanard-Koenders, MSJ, RPh, Executive Director: kari.shanard-koenders@state.sd.us

Melissa DeNoon, RPh, PDMP Director: melissa.denoon@state.sd.us

Tyler Laetsch, PharmD, RPh, Pharmacy Inspector: tyler.laetsch@state.sd.us

Carol Smith, RPh, Pharmacy Inspector: carol.smith@state.sd.us

Lee Cordell, PharmD, RPh, Pharmacy Inspector: lee.cordell@state.sd.us

Beth Windschitl, Senior Secretary: beth.windschitl@state.sd.us

Melanie Houg, PDMP Assistant: melanie.houg@state.sd.us

Rhea Kontos, Senior Secretary: rhea.kontos@state.sd.us

PDMP Sign-up and Data Access Website: *https://southdakota.pmpaware.net/login*

The South Dakota Board of Pharmacy News is published by the South Dakota Board of Pharmacy and the National Association of Boards of Pharmacy Foundation® (NABPF®) to promote compliance of pharmacy and drug law. The opinions and views expressed in this publication do not necessarily reflect the official views, opinions, or policies of NABPF or the Board unless expressly so stated.

Kari Shanard-Koenders, MSJ, RPh - State News Editor
Lemrey "Al" Carter, PharmD, MS, RPh - National News Editor & Executive Editor
Megan Pellegrini - Publications and Editorial Manager

4001 W Valhalla Blvd, Suite 106 | Sioux Falls, SD 57106 | 605/362-2737 | www.pharmacy.sd.gov